EMS to Acquire Sanofi’s Medley, Cementing Lead in Brazil’s Generics Market

Overview

• EMS and Sanofi signed a definitive deal on March 6 for the sale of 100% of Medley to EMS, with no price disclosed.
• Press reports value the transaction at about R$3.2 billion, with some outlets citing roughly R$3.6 billion.
• The closing depends on CADE review and other conditions, and Medley will continue under Sanofi’s management until approval.
• EMS projects its generics share to rise from about 23–24% by another 7–8%, reaching roughly 30–31% after the transaction.
• The sale followed a competitive process that drew bids from Sun Pharma, Hypera, Biolab, and Aché, and EMS plans to keep and possibly invest in Medley’s Campinas plant while evaluating new capacity in Manaus.